Immune
The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Liu D, Yu Z, Yin J, et al. · BMJ · 2025
PMID: 39814420 · DOI: 10.1136/bmj-2024-082583
Summary
Multicenter double-blind placebo-controlled phase 3 trial (TESTS) of subcutaneous thymosin alpha-1 in 1106 adults with sepsis. Primary endpoint: 28-day all-cause mortality; secondary: organ-failure-free days.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Thymosin Alpha-1 5mg28-residue acetylated thymic peptide studied in immune-modulation research.
Guides covering this compound
More Immune citations
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialCrit Care · 2013
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialLiver · 1996
- The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialJ Viral Hepat · 2005